Abstract
Bacteroides fragilis is responsible for most anaerobic infections in man. Most isolates of B. fragilis show resistance to beta-lactam antibiotics. This resistance might be due to beta-lactamase production or permeability barrier in the cell wall. B. fragilis produce beta-lactamase with mainly cephalosporinase activity. Other Bacteroides species such as B. clostridiformis, B. melaninogenicus and B. oralis also produce beta-lactamase but with different biochemical characteristics.
MeSH terms
-
Amidohydrolases / metabolism*
-
Anti-Bacterial Agents / therapeutic use
-
Bacteriological Techniques
-
Bacteroides / enzymology*
-
Bacteroides Infections / drug therapy*
-
Bacteroides fragilis / enzymology
-
Cefamandole / therapeutic use
-
Cefoxitin / therapeutic use
-
Cell Wall / enzymology
-
Cephalosporinase / metabolism*
-
Cephalosporins / therapeutic use*
-
Furans / therapeutic use
-
Humans
-
Isoelectric Focusing
-
Penicillin G / therapeutic use
-
Penicillin Resistance
-
Penicillinase / metabolism*
-
Penicillins / therapeutic use
-
Prevotella melaninogenica / enzymology
-
Species Specificity
-
beta-Lactams / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Furans
-
Penicillins
-
beta-Lactams
-
Cefamandole
-
Cefoxitin
-
Amidohydrolases
-
Cephalosporinase
-
Penicillinase
-
Penicillin G